Ibrutinib is a Bruton tyrosine kinase (BTK) inhibitor that has shown significant efficacy in patients with lymphoid carcinomas, mostly chronic lymphocytic leukemia (CLL). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.